Abstract: A system for controlling temperature of intravenous fluids includes a thermal treatment device and a temperature sensing device to measure a temperature of the fluid flowing through the sensor. The temperature sensing device may simultaneously collect two temperature measurements. For example, the sensing device may include sensors that measure the temperature of the fluid at two disparate locations along the medical fluid line. Additionally, the sensors may measure the temperature of the fluid within the medical fluid line, as well as the ambient temperature outside of the line. The thermal treatment device includes a conduit configured to have a nonlinear flow path through the device. The thermal treatment device thermally treats fluid within the conduit to a desired temperature or range.

Abstract: A thermal treatment system for thermally treating objects includes a housing including a top surface, a basin recessed into the top surface and configured to contain a liquid medium, where the liquid medium thermally treats objects placed within the liquid medium, and a ramp structure disposed on the top surface of the housing. The ramp structure is configured to support at least one object such that a first end portion of the object is disposed within the liquid medium while a second end portion of the object is supported by the ramp structure outside of the liquid medium.

Abstract: A thermal treatment system for thermally treating objects includes a housing including a top surface, a basin recessed into the top surface and configured to contain a liquid medium, where the liquid medium thermally treats objects placed within the liquid medium, and a ramp structure disposed on the top surface of the housing. The ramp structure is configured to support at least one object such that a first end portion of the object is disposed within the liquid medium while a second end portion of the object is supported by the ramp structure outside of the liquid medium.

Abstract: A medical device with a hydrophilic and lubricious coating, wherein the coating includes a hydrophilic polymeric unit layer deposited on the medical device and cross-linked with a plasma deposited double bond monomer. The hydrophilic polymeric unit can include ethylene oxide with one or more primary or secondary alcohol groups or glycosaminoglycans such as hyaluronic acid, and the double bond monomer includes monomers containing at least one double bond, preferably a C?C, C?N or C?O bond, including N-trimethylsilyl-allylamine, ethylene, propylene and allyl alcohol.

Abstract: The present invention provides a bioactive coating composition, method and devices for bodily fluid-contacting surfaces. The coating comprises a complex of Formula II: wherein R1 is an C1-18alkyl or C6-32aryl group, each R2 is independently selected from the group consisting of C1-18alkyl and C6-32aryl, R3 is N or O, n is a number from 1 to 10, and x in a number from 1 to about 30, directly bound to a heparin-activity molecule via covalent bonding, with one or more bioactive molecules bound to the heparin-activity molecule.

Abstract: A medical device with a hydrophilic and lubricious coating, wherein the coating includes a hydrophilic polymeric unit layer deposited on the medical device and cross-linked with a plasma deposited double bond monomer. The hydrophilic polymeric unit can include ethylene oxide with one or more primary or secondary alcohol groups or glycosaminoglycans such as hyaluronic acid, and the double bond monomer includes monomers containing at least one double bond, preferably a C═C, C═N or C═O bond, including N-trimethylsilyl-allylamine, ethylene, propylene and allyl alcohol.

Abstract: The present invention provides a bioactive coating composition, method and devices for bodily fluid-contacting surfaces. The coating comprises a complex of Formula II: wherein R1 is an C1-18alkyl or C6-32aryl group, each R2 is independently selected from the group consisting of C1-18alkyl and C6-32aryl, R3 is N or O, n is a number from 1 to 10, and x in a number from 1 to about 30, directly bound to a heparin-activity molecule via covalent bonding, with one or more bioactive molecules bound to the heparin-activity molecule. The bioactive molecule may be an adhesive molecule such as fibronectin, a growth factor such as basic fibroblast growth factor, or any other bioactive molecule that binds, by any mechanism, to a heparin-activity molecule.

Abstract: A method for making a hydrophilic and lubricious coating, the coating so made and a medical device including such coating, wherein the coating includes a hydrophilic polymeric unit layer cross-linked with a plasma deposited double bond monomer. The hydrophilic polymeric unit can include ethylene oxide with one or more primary or secondary alcohol groups or glycosaminoglycans such as hyaluronic acid, and the double bond monomer includes monomers containing at least one double bond, preferably a C═C, C═N or C═O bond, including N-trimethylsilyl-allylamine, ethylene, propylene and allyl alcohol. The invention also provides products containing such coatings and their uses in medical, pharmaceutical and cosmetic applications.

Abstract: Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue is modified by plasma treatment in a plasma including nitrogen-containing molecules and oxygen-containing molecules and by application of a biologically compatible coating, preferably by plasma treatment in a plasma including polymerized hydrocyclosiloxane monomers. The nitrogen-containing molecules include NH3, (NH4)+, N2O, NO, NO2 and N2O4, and the oxygen-containing molecules include O2 and O3. The plasma-modified contacting surface exhibits decreased adhesion of at least some mammalian cells, such as platelets and leukocytes, decreased restenosis when used with stents, and increased apoptosis. Additional layers may be applied, including amine-providing groups such as N-trimethylsilyl-allylamine, polyoxyalkylene tethers, and bioactive compounds.

Abstract: The present invention provides an anti-thrombogenic and cellular-adhesion coating composition for blood-contacting surfaces. The coating comprises a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: wherein R1 is an C1-18 alkyl or C6-32 aryl group, each R2 is independently selected from the group consisting of C1-18 alkyl and C6-32 aryl, R3 is N or O, n is a number from 1 to 10, directly bound to a heparin molecule via covalent bonding, with an adhesive molecule directly bound to the heparin molecule. In one embodiment, the coating comprises benzyl-(1,2 dimethyl)disilyl heparin, wherein an adhesive molecule, such as fibronectin, is bound to the heparin.

Abstract: A nucleic acid coating composition including a polyanion bound, directly or through one or more intermediates, to a medical device surface, with a condensate comprising a polycation and nucleic acid bound to the polyanion, devices incorporating such coating compositions, and methods for making. In one embodiment, a silyl-heparin complex is provided, bound to a medical device surface by hydrophobic interaction with the silyl moiety, with a polycation and nucleic acid condensate bound to the heparin by electrostatic interaction.

Abstract: A method for making a hydrophilic and lubricious coating, the coating so made and a medical device including such coating, wherein the coating includes a hydrophilic polymeric unit layer cross-linked with a plasma deposited double bond monomer. The hydrophilic polymeric unit can include ethylene oxide with one or more primary or secondary alcohol groups or glycosaminoglycans such as hyaluronic acid, and the double bond monomer includes monomers containing at least one double bond, preferably a C═C, C═N or C═O bond, including N-trimethylsilyl-allylamine, ethylene, propylene and allyl alcohol. The invention also provides products containing such coatings and their uses in medical, pharmaceutical and cosmetic applications.

Abstract: A nucleic acid coating composition including a polyanion bound, directly or through one or more intermediates, to a medical device surface, with a condensate comprising a polycation and nucleic acid bound to the polyanion, devices incorporating such coating compositions, and methods for making. In one embodiment, a silyl-heparin complex is provided, bound to a medical device surface by hydrophobic interaction with the silyl moiety, with a polycation and nucleic acid condensate bound to the heparin by electrostatic interaction.

Abstract: The present invention provides an anti-thrombogenic and cellular-adhesion coating composition for blood-contacting surfaces.

Abstract: The present invention provides an anti-thrombogenic and cellular-adhesion coating composition for blood-contacting surfaces. The coating comprises a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: wherein R1 is an C1-18 alkyl or C6-32 aryl group, each R2 is independently selected from the group consisting of C1-18 alkyl and C6-32 aryl, R3 is N or O, n is a number from 1 to 10, directly bound to a heparin molecule via covalent bonding, with an adhesive molecule directly bound to the heparin molecule. In one embodiment, the coating comprises benzyl-(1,2 dimethyl)disilyl heparin, wherein an adhesive molecule, such as fibronectin, is bound to the heparin.

Abstract: The present invention provides an anti-thrombogenic coating composition for blood-contacting surfaces. The coating comprises a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: ##STR1## wherein R.sub.1 is a C.sub.1-8 alkyl or C.sub.6-32 aryl group, each R.sub.2 is independently selected from the group consisting of C.sub.1-8 alkyl and C.sub.6-32 aryl, R.sub.3 is N or O, and n is a number from 1 to 10, directly bound to a heparin molecule via covalent bonding.

Abstract: Several poly(ethylene glycol) mixed carbonates and their preparation are closed. These carbonates are synthesized by conversion of polyethylene glycol first to the chloroformate then by reaction with the hydroxyl group of N-hydroxybenzotriazole or 2-hydroxypyrimidine or N-hydroxy-2-pyrrolidinone. These mixed carbonate analogs smoothly react with amino groups in aminoglycans and protein and amino containing surfaces to form stable, hydrolysis resistant carbamate linkages.